The Molecular Pathogenesis of Late-onset Fuchs' Endothelial Corneal Dystrophy

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01795001

Enrollment

460

Registered

2013-02-20

Start date

2012-10-31

Completion date

2017-09-13

Last updated

2018-05-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fuchs' Endothelial Dystrophy

Keywords

pathophysiology

Brief summary

The purpose of this study is to gain further insights into the molecular pathogenesis of Fuchs' endothelial corneal dystrophy (FECD), to identify targets for potential specific drug therapy.

Interventions

OTHERNo intervention

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* FECD * normal corneas (including enucleations for uveal melanoma) * non-FECD oedematous corneas

Exclusion criteria

* prior irradiation therapy for uveal melanoma * corneal extension of uveal melanoma

Design outcomes

Primary

Measure	Time frame	Description
cytokine levels	at time of prelevation (once, no intervention)	dosage of cytokine levels in aqueous humour (exploratory, non-interventional study)
gene expression levels	at time of prelevation (once, no intervention)	microarray expression analysis, reverse transcriptase - quantitative polymerase chain reaction (RT-qPCR), RNA-sequencing (exploratory, non-interventional study)
protein content	at time of prelevation (once, no intervention)	immunohistochemistry and immunofluorescence

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026